Lupeol

Lupeol at a Glance

Lupeol is a lupane-type pentacyclic triterpene found widely across edible plants — mango, dandelion, nettle and many others — and the direct precursor of betulinic acid.

It has a large preclinical anticancer and anti-inflammatory literature and essentially no human trials, a pattern shared by most dietary triterpenes.

Its poor water solubility is the recurring obstacle to developing it further.

What It's Used For

Lupeol is a pentacyclic triterpene of the lupane class found across a very wide range of edible plants — mango, dandelion, nettle, muira puama and many medicinal herbs — usually as a minor part of the triterpene fraction. It is one of the more heavily studied plant triterpenes, and its literature has a clear shape: a large, mechanistically coherent preclinical anticancer and anti-inflammatory body, and essentially no human trials. The single most important qualifier is pharmacokinetic — lupeol is extremely lipophilic (log P ≈ 7.7) with very low aqueous solubility and poor oral bioavailability ^{11,12Reference 11Cháirez-Ramírez MH et al. · 2019AnimalAbsorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI(+)-MS/MSView study →Reference 12Dalimunthe A et al. · 2024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}, so the striking in-vitro potencies are not obviously reachable from oral intake. Its mechanism is genuinely multi-target: modulation of Wnt/β-catenin, NF-κB, PI3K/Akt and STAT3 signaling ^{3,4,7Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →Reference 4Saleem M et al. · 2009Lupeol inhibits proliferation of human prostate cancer cells by targeting β-catenin signallingView study →Reference 7Siveen KS et al. · 2014Negative regulation of the STAT-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cellsView study →}.

Broad preclinical anticancer signal:consistent activity across many tumor models via Wnt/β-catenin, NF-κB and PI3K/Akt ^{3,4,5Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →Reference 4Saleem M et al. · 2009Lupeol inhibits proliferation of human prostate cancer cells by targeting β-catenin signallingView study →Reference 5Tarapore RS et al. · 2010Specific targeting of Wnt/β-catenin signalling in human melanoma cells by the dietary triterpene lupeolView study →} — but entirely cell-line and rodent.

Topical is the most plausible near-term route:skin models of inflammation and carcinogenesis respond to topical lupeol ^{3,9Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →Reference 9Bae S et al. · 2023AnimalLupeol alleviates atopic-dermatitis-like skin inflammation in DNCB/Dermatophagoides farinae-induced miceView study →}, sidestepping the oral-absorption problem.

The honest headline:there are no human trials of any kind, and poor oral bioavailability means preclinical potency should not be read as oral human efficacy ^{11,12Reference 11Cháirez-Ramírez MH et al. · 2019AnimalAbsorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI(+)-MS/MSView study →Reference 12Dalimunthe A et al. · 2024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every application here is preclinical, so scores stay low by design. Each application links to its write-up.

Mechanisms

Target / pathway	Effect	Relevant to
Wnt / β-catenin (↓ nuclear β-catenin, GSK3β/MMP-2)	↓ proliferation, invasion, metastasis signaling	prostate cancermelanoma
NF-κB (↓ activation)	anti-inflammatory; anti-tumor-promoting	skin carcinogenesisarthritis
PI3K / Akt (↓ signaling)	pro-apoptotic; blocks survival signaling	skin cancer
STAT3 (↓ Tyr705 via ↑ SHP-2)	growth inhibition, apoptosis	hepatocellular carcinoma
cFLIP / MYC (↓; in-silico + in-vitro)	restores apoptosis sensitivity, chemosensitization	therapy-resistant prostate cancer

Pharmacokinetics

Load-bearing and the central limitation. Lupeol is highly lipophilic (octanol/water log P ≈ 7.67) with extremely low aqueous solubility, which severely limits its dissolution in GI fluids and hence oral absorption ^{12Reference 12Dalimunthe A et al. · 2024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}. In-vivo work confirms poor, erratic systemic exposure — absorption and tissue distribution in mice, characterized by mass spectrometry, document the low-exposure profile ^{11Reference 11Cháirez-Ramírez MH et al. · 2019AnimalAbsorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI(+)-MS/MSView study →} — which is precisely why the field has pivoted to nanostructured lipid carriers, solid lipid nanoparticles and other delivery engineering to raise bioavailability ^{12Reference 12Dalimunthe A et al. · 2024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}. The practical implication: the impressive in-vitro concentrations are not obviously achievable from oral intake of unformulated lupeol, so preclinical potency should not be read as oral human efficacy.

Clinical trials

There are no completed randomized controlled human efficacy trials of isolated lupeol for any indication. The entire evidence base is in-vitro and animal, aggregated in preclinical reviews ^{1,2,12Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →Reference 12Dalimunthe A et al. · 2024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}. Any human-facing claim should be labeled preclinical/investigational only.

Completed	Planned	Terminated	Preclinical
—(none)	—	—	Extensive

Last checked: July 2026.

Toxicity & Safety

Lupeol’s low observed toxicity is a genuine point in its favor: it is a normal constituent of many edible fruits and vegetables, is repeatedly reported as well tolerated at high oral doses in rodents, and appears not to harm normal cells at effective doses in the preclinical literature ^{1,2Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →} — the rat anti-arthritic work, for instance, produced its effect without ulcerogenic, antipyretic or antinociceptive liability ^{8Reference 8Geetha T · 2001AnimalAnti-inflammatory activity of lupeol and lupeol linoleate in ratsView study →}. That said, formal acute/chronic toxicology and a clean LD50 for isolated lupeol are not well established, so the “low toxicity” verdict rests on aggregate preclinical observation plus dietary ubiquity rather than regulatory-grade studies, and the isolated concentrated-supplement profile in humans is uncharacterized. There is no human drug-interaction data; because lupeol modulates NF-κB, PI3K/Akt, STAT3 and β-catenin and can chemosensitize cancer cells ^{6Reference 6Maurya SK et al. · 2022Role of lupeol in chemosensitising therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in-silico and in-vitro studiesView study →}, theoretical additive or interfering effects with anti-inflammatory or oncologic drugs cannot be excluded.

Dosage

There is no human dose for lupeol, and the following are research doses, not recommendations. Rodent studies used roughly 1–2 mg/mouse topically for skin models ^{3Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →} and oral or parenteral doses of tens of mg/kg for systemic anti-inflammatory and anticancer models ^{8,2Reference 8Geetha T · 2001AnimalAnti-inflammatory activity of lupeol and lupeol linoleate in ratsView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →}. These do not translate to a human supplement dose, and the poor oral bioavailability means an unformulated oral dose has unpredictable exposure.

References

Saleem M (2009). Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Letters. https://pubmed.ncbi.nlm.nih.gov/19464787/
Siddique HR, Saleem M (2011). Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sciences. https://pubmed.ncbi.nlm.nih.gov/21118697/
Saleem M, et al. (2004). Lupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene. https://pubmed.ncbi.nlm.nih.gov/15122342/
Saleem M, et al. (2009). Lupeol inhibits proliferation of human prostate cancer cells by targeting β-catenin signalling. Carcinogenesis. https://pubmed.ncbi.nlm.nih.gov/19233958/
Tarapore RS, et al. (2010). Specific targeting of Wnt/β-catenin signalling in human melanoma cells by the dietary triterpene lupeol. Carcinogenesis. https://pubmed.ncbi.nlm.nih.gov/20732907/
Maurya SK, Fatma H, Maurya AK, et al. (2022). Role of lupeol in chemosensitising therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in-silico and in-vitro studies. In Silico Pharmacology. https://pubmed.ncbi.nlm.nih.gov/36072559/
Siveen KS, Nguyen AH, Lee JH, et al. (2014). Negative regulation of the STAT-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells. British Journal of Cancer. https://pubmed.ncbi.nlm.nih.gov/25101566/
Geetha T, Varalakshmi P (2001). Anti-inflammatory activity of lupeol and lupeol linoleate in rats. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/11378285/
Bae S, Jeong NH, Choi YA, et al. (2023). Lupeol alleviates atopic-dermatitis-like skin inflammation in DNCB/Dermatophagoides farinae-induced mice. BMC Pharmacology & Toxicology. https://pubmed.ncbi.nlm.nih.gov/37098554/
Malik A, Jamil U, Butt TT, et al. (2019). In-silico and in-vitro studies of lupeol and iso-orientin as potential antidiabetic agents in a rat model. Drug Design, Development and Therapy. https://pubmed.ncbi.nlm.nih.gov/31123393/
Cháirez-Ramírez MH, Gallegos-Infante JA, Moreno-Jiménez MR, et al. (2019). Absorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI(+)-MS/MS. Biomedical Chromatography. https://pubmed.ncbi.nlm.nih.gov/30419143/
Dalimunthe A, Carensia Gunawan M, Dhiya Utari Z, et al. (2024). In-depth analysis of lupeol: delving into the diverse pharmacological profile. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/39605919/
Wang CM, Chen HT, Wu ZY, et al. (2016). Antibacterial and synergistic activity of pentacyclic triterpenoids isolated from Alstonia scholaris. Molecules. https://pubmed.ncbi.nlm.nih.gov/26821000/